100 mg tablet: This product should be administered to pregnant women or women who may possibly be pregnant, only if the expected therapeutic benefits outweigh the possible risks associated with treatment. [The safety of this product during pregnancy has not been established.]
200 mg tablet: Pregnancy: Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see Pharmacology: Toxicology: Preclinical safety data under Actions). There are no adequate data from the use of cefditoren pivoxil in pregnant women.
Lactation: There is insufficient evidence available on whether cefditoren is present in human milk. Therefore, the administration of MEIACT is not recommended during lactation.